Effects of DDAVP (1-deamino-8-D arginine vasopressin) infusion on parameters of hemostasis in patients with liver cirrhosis

Completed

• Conditions: 10064477; 10019654; 10025309; Liver failure; liver fibrosis

• Registration Number: NL-OMON39451
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

Research group:
- Leeftijd > 18 yrs
- Non-cholestatic cirrhosis, with moderate to severe disease (Child B or C)
- Schedukled to visit the policlinic hepatology for routine check-up
- Informed consent
Control group (samples obtained in Erasmus MC Rotterdam for different research project)
- age>18 yrs
- hemophilia type A
- Informed consent

Exclusion Criteria

- Age < 18 yrs
- Biliary cirrhosis
- Malignancies
- Renal failure requiring intervention with drugs or dialysis
- Active infection requiring intervention
- Recent (< 7 days before administration) transfusion of plasma or platelet concentrates
- Use of aspirin, other anti-platelet drugs, antifibrinolytic agents or vitamin K antagonists
- Angina Pectoris
- One of the following disorders of coagulation: hemophilia, Von Willebrand's disease, antithrombin deficiency, protein C deficiency or protein S deficiency

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Study endpoint will be time-dependent changes in laboratory parameters in<br /><br>patients with cirrhosis compared to these changes in patients with hemophilia,<br /><br>in which the efficacy of DDAVP has been well established. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To elucidate possible mechanisms involved in the supranormal levels of VWF and<br /><br>factor VIII in patients with liver cirrhosis.</p><br>